MAAT.PA MaaT Pharma EURONEXT 27 Jan 2026 up 19.35%: short-term test of €8.28 possible
MAAT.PA stock surged intraday on 27 Jan 2026 to €6.66, a +19.35% move from yesterday’s close of €5.58. Volume jumped to 191,519 shares, about 4.21x average, making MaaT Pharma SA (MAAT.PA) one of today’s top gainers on EURONEXT in Europe. The rally follows mixed clinical updates and active trading interest in the biotechnology sector. We examine what drove the spike, how fundamentals and technicals align, and where the stock could head next.
Intraday move and drivers for MAAT.PA stock
MAAT.PA rose to a day high of €6.66 after opening at €6.14 and trading as high as €6.66. The intraday gain of +19.35% paired with volume 191,519 shows short-term buying pressure. News flows cited clinical progress and sector momentum, which often lifts small-cap biotech names.
Traders note the stock beat its 50-day average of €4.52 and 200-day average of €4.76. That gap signals fresh momentum and explains why MAAT.PA is among top gainers on EURONEXT today.
Fundamentals, valuation and MAAT Pharma overview
MaaT Pharma SA is a clinical-stage biotechnology company focused on microbiome biotherapies for cancer. The company is headquartered in Lyon, France, and trades on EURONEXT in EUR. Revenue per share TTM is €0.26 and EPS is -€2.15, producing a negative P/E of -2.85.
Key ratios show heavy R&D spend and a thin revenue base. Market cap stands at €92.50m with shares outstanding 15,113,567. Price-to-sales is 23.58 and price-to-book is 11.15, reflecting high valuation for limited revenue and recurring negative earnings.
Technical setup and trading metrics for MAAT.PA stock
Momentum indicators are bullish but near overbought readings. The RSI sits at 69.70 and CCI at 182.58, suggesting short-term strength and limited immediate upside without a pullback. The ADX at 32.65 signals a strong trend.
Price sits well above the 50- and 200-day averages by 47.36% and 40.00% respectively. On balance volume and MFI confirm buying interest. Traders should watch the prior year high €8.28 as a clear resistance.
Meyka AI rates MAAT.PA with a score out of 100
Meyka AI rates MAAT.PA with a score of 62.10 out of 100 (Grade: B, Suggestion: HOLD). This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The grade reflects mixed fundamentals, improving momentum, and biotech sector risk.
This score is informational. These grades are not guaranteed and we are not financial advisors.
Meyka AI’s forecast model projects and price scenarios
Meyka AI’s forecast model projects a yearly price of €1.55, a model-based projection and not a guarantee. That projection implies an implied downside of -76.71% versus the current €6.66. Forecasts are model-based projections and not guarantees.
Scenario targets: a short-term technical target near the year high €8.28 is possible with momentum. A base-case 12-month nominal target would be €4.00 if trial news stalls. The bearish model output at €1.55 assumes revenue traction fails to materialize.
Risks, opportunities and sector context for MAAT.PA stock
Risk profile is high for MAAT.PA because it is clinical-stage with negative earnings and thin liquidity. Key risks include trial setbacks, dilution, and limited cash runway. Debt-to-equity ratio is 1.74, adding leverage risk.
Opportunities include successful clinical readouts and consolidation in the microbiome biotech space. Healthcare sector performance is muted year-to-date, but biotech-specific catalysts can create sharp moves, as seen in today’s top-gainer pattern.
Final Thoughts
MAAT.PA stock’s intraday jump to €6.66 on 27 Jan 2026 highlights how clinical news and volume spikes move small-cap biotech names on EURONEXT. Short-term traders may chase momentum toward the prior high of €8.28, while longer-term investors must weigh weak earnings, negative EPS -€2.15, and high valuation metrics like P/S 23.58 and P/B 11.15. Meyka AI’s forecast model projects a yearly price of €1.55, implying -76.71% from today’s price; this is a model output, not a promise. Our view is scenario-driven: a bullish path to roughly €8.00 requires positive trial updates or clearer commercial pathways. A conservative 12-month base-case target near €4.00 reflects typical biotech volatility and funding risk. Use tight risk controls, monitor the company’s earnings announcement schedule, and consider position sizing carefully. Meyka AI, an AI-powered market analysis platform, provides these data-driven views to help inform your decisions.
FAQs
What caused the MAAT.PA stock jump today?
The intraday jump to €6.66 was driven by increased trading volume and renewed interest in clinical updates. High relative volume 191,519 shares and biotech sector momentum pushed MAAT.PA higher on EURONEXT.
What is Meyka AI’s forecast for MAAT.PA stock?
Meyka AI’s forecast model projects a yearly price of €1.55, which implies an estimated downside of -76.71% versus the current €6.66. Forecasts are model-based projections and not guarantees.
How does MAAT.PA stock rate by Meyka AI?
Meyka AI rates MAAT.PA with a score of 62.10 out of 100 (Grade: B, Suggestion: HOLD). This factors in benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus.
What key metrics should investors watch for MAAT.PA stock?
Monitor trial readouts, cash runway, EPS -€2.15, market cap €92.50m, and volume relative to average. Watch resistance at €8.28 and support near the 50-day average of €4.52.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
